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Summary
Background. Estrogen plays a central role in breast cancer pathogenesis and many potent risk factors for the
development of the disease can be explained in terms of increased lifetime exposure to estrogen. Although estrogen
regulated genes have been identified, those critically involved in growth regulation remain elusive.
Methods. To identify candidate genes involved in estrogen stimulated breast cancer growth, DNA microarray
based gene expression profiles were generated from three estrogen receptor a (ERa) positive breast cancer cell lines
grown under multiple stimulatory and inhibitory conditions.
Results. Only three genes were significantly induced by 17b-estradiol (E2) relative to control in all three cell lines:
GREB1, stromal cell-derived factor 1 (SDF-1) and trefoil factor 1 (pS2). Quantitative real-time PCR assays con-
firmed that in all three cell lines, GREB1 was induced by E2, but not by the antiestrogens tamoxifen (TAM) or ICI
182,780. GREB1 expression level was strongly correlated with ERa positivity in 39 breast cancer cell lines of known
ERa expression status. GREB1 induction by E2 was rapid (7.3 fold by 2 h for MCF-7) and mirrored the fraction of
cells entering S-phase when released from an estrogen deprivation induced cell arrest. Suppression of GREB1 using
siRNA blocked estrogen induced growth in MCF-7 cells and caused a paradoxical E2 induced growth inhibition.
Conclusion. These data suggest that GREB1 is critically involved in the estrogen induced growth of breast cancer
cells and has the potential of being a clinical marker for response to endocrine therapy as well as a potential
therapeutic target.
Abbreviations: E2: 17b-estradiol; ERa: estrogen receptor alpha; ERb: estrogen receptor beta; FBS: fetal bovine
serum; GREB1: gene regulated in breast cancer 1; pS2: trefoil factor 1; SDF-1: stromal cell-derived factor 1
Introduction
Breast cancer is the most common malignancy in women
in the Western world with over 200,000 new cases per
year in the United States alone [1]. It has been well
established that the hormone estrogen plays a significant
role in breast cancer development and progression [2].
Many of the most potent risk factors for the develop-
ment of breast cancer can be explained in terms of in-
creased lifetime exposure to estrogen, and drugs that
block estrogen action have been shown to prevent breast
cancer [3]. Estrogen mediates many of its physiological
effects by binding to specific steroid receptors, estrogen
receptor alpha (ERa) and beta (ERb). These receptors
are the key regulators of estrogen signaling and can
mediate a number of effects within the cell mainly by
altering the expression of genes via direct interaction
with their promoters or through binding to other pro-
teins, which in turn interact with and regulate gene
promoters [4]. While the hormonal dependence of some
human breast cancer has provided many useful inter-
ventions, a failure to fully understand both the exact
genes uniquely responsible for hormone stimulation of
growth and pathways of growth control in hormone
independent states has limited therapy.
Our laboratory is interested in identifying the key
genes uniquely responsible for hormone stimulated
growth. We used Affymetrix U133A Genechip Arrays
to analyze the gene expression patterns induced in three
separate ERa-positive, estrogen dependent breast cancer
cell lines (MCF-7, T47D and BT-474) grown in steroid
depleted medium or in the presence of E2, 10% fetal
bovine serum (FBS), TAM or ICI 182,780. These lines
are classic estrogen dependent breast cancer cells whose
growth in vitro and in vivo can be blocked by estrogen
depletion and with antiestrogens [5]. Specifically, we
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sought genes with expression patterns common to all
three cell lines that were correlated with the proliferative
behavior of the cells in response to estrogen or anties-
trogen treatment. In this study we describe the detailed
analysis of one of the genes (GREB1) identified using
this method. Our results show that GREB1 is an early
response gene regulated by ERa both in vitro and in vivo
and is a key regulator of estrogen induced breast cancer
growth.
Methods
Cell lines, culture conditions and growth assays
Tumor cell lines were maintained and growth assays
performed as described previously [5]. For defined
estrogen culture experiments, cells were washed and
grown in steroid depleted media (phenol red-free IMEM
supplemented with 10% charcoal stripped calf bovine
serum – Valley Biomedical Products, VA) as described
previously [5]. For growth assays, cells were plated in
steroid depleted media at 2 · 103 cells/well in 96-well
plates (Falcon, Lincoln Park, NJ) and cultured for
3 days before treatment with estrogen, antiestrogens or
the appropriate vehicle control (ethanol 0.1%). Relative
cell number was determined using the crystal violet as-
sayed as described previously [6].
RNA extraction
Total RNA was isolated using TRIzol Reagent (Invi-
trogen, CA) according to the manufacture’s instruc-
tions. Yield and quality were determined by
spectrophotometry (Beckman DU 640, Beckman
Coulter, Inc., Fullerton, CA) and using a Bioanalyzer
RNA 6000 Nano chip (Agilent Technologies, Palo Alto,
CA). The RNA from the panel of breast cancer cell lines
grown under standard culture conditions was kindly
provided by Dr Joe W. Gray at the University of Cali-
fornia Breast SPORE program. All samples were stored
at )80 C. RNA for microarray analysis was labeled
and hybridized according the Affymetrix protocol (Af-
fymetrix GeneChip Expression Analysis Technical
Manual, Rev. 3) by the University of Michigan Com-
prehensive Cancer Center Affymetrix and cDNA
Microarray Core Facility.
Affymetrix microarray analysis
Gene expression patterns were determined using Af-
fymetrix U133A Genechip Arrays. Arrays were nor-
malized and compared using DNA-Chip Analyzer
software (dChip) [7]. Array samples were then compared
to the control sample using a 90% confidence interval
for fold change with the cutoffs for fold change and
p-value being 1.2 and 0.1 respectively. Hierarchical
clustering was performed using a subset of genes in
which the variation across samples was greatest. All
samples with a standard deviation/mean value of greater
than 0.375 were included in this subset.
Flow cytometry
Cells (7.5 · 105) were washed once with 1XPBS and
re-suspended in 0.5 ml 1XPBS before drop-wise addi-
tion of ice cold ethanol (0.5 ml). The samples were
incubated at room temperature for 30 min, and then
centrifuged at 50 · g for 5 min. The supernatant was
removed and the cells stained in 0.5 ml of a solution of
50 ug/ml Propidium Iodide and 100 lg/ml Ribonuclease
A (Sigma-Aldrich Co., St. Louis, MO). The samples
were incubated in the dark at room temperature for
30 min before analysis using a FACStarPlusTM cell
sorter. S-phase fraction was estimated using MultiCycle/
MultiPlus software (Phoenix Flow Systems Inc., San
Diego, CA).
Real-time PCR
GREB1 has three known alternative splice variants:
GREB1a – 8482-bp (accession number =
NM_014668), GREB1b – 2347-bp (accession num-
ber = NM_033090), and GREB1c – 2341-bp (accession
number = NM_148903). Two separate quantitative
real-time PCR assays were developed that detect
GREB1a or all three transcripts. Primers were designed
using the Primer3 program from the Whitehead Institute
(www-genome.wi.mit.edu) and purchased from Inte-
grated DNA Technologies, Inc. (Coralville, IA). Total
RNA (1 lg) was reverse transcribed using Reverse
Transcription System (Promega, Madison, WI) and
quantitative real-time PCR was performed using an
iCycler Thermal Cycler (Bio-Rad, Hercules, CA). Two
and a half % of the cDNA was amplified in 25 ll reac-
tions using Platinum Supermix UDG (Invitrogen Corp.,
Carlsbad, CA), 250 nM of each primer, 10 nM fluores-
cein (BioRad Inc., Hercules, CA), and Syber Green. The
GREB1a forward primer 5¢-AAA TCG AGG ATG
TGG AGTG-3¢ and GREB1a reverse primer 5¢-TCT
CAC CAA GCA GGA GGA G-3¢ amplify a 158-bp
fragment spanning nucleotides 3317–3475 (accession
number = NM_033090) a region specific for GREB1a.
The GREB1a–c forward primer 5¢-CAA AGA ATA
ACC TGT TGG CCC TGC-3¢ and reverse primer 5¢-
GAC ATG CCT GCG CTC TCA TAC TTA-3¢ amplify
a 172-bp fragment spanning nucleotides 1160–1331 a
region to common to all three splice variants. Real-time
PCR assay for the pS2 gene was adapted from Bosma
et al. [8]. To control for RNA quality and quantity we
used two separate housekeeping genes, glyceraldehydes-
3-phosphate dehydrogenase (GAP DH) and estradiol-
independent mRNA 36B4 [9] with the GAPDH forward
primer 5¢-GAA GGT GAA GGT CGG AGT C-3¢ and
reverse primer 5¢-GAA GAT GGT GAT GGG ATT
TC-3¢ and 36B4 forward primer 5¢-GTG TTC GAC
AAT GGC AGC AT-3¢ and reverse primer 5¢-GAC
ACC CTC CAG GAA GCG A-3¢. For sequence
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verification, PCR products were cloned into the pCR
2.1 vector using the TA Cloning Kit (Invitrogen Corp.,
Carlsbad, CA) according to the manufacture’s instruc-
tion and representative clones subjected to dideoxy-
sequencing.
To compare the relative efficiencies of each PCR
reaction, serial dilutions (100, 10, 1, 0.1 and 0.01 pg) of
template were prepared using GREB1 or housekeeping
gene plasmid DNA. To evaluate the quality of product
of real-time PCR assays, melt curve analysis was
performed after each assay. Relative expression was
determined using the DDCT method with either GAPDH
or 36B4 as the reference gene [10].
GREB1 mRNA suppression using siRNA
Four synthetic small interfering RNA (siRNA) duplexes
were designed using standard criteria and purchased
from Dharmacon (Lafayette, CO). A non-silencing
siRNA duplex, with no homology to any known se-
quence was used as a control (catalog #D-001206-09,
Dharmacon Inc., Lafayette, CO). MCF-7 cells were
cultured for four days in hormone-free medium as de-
scribed above, then transfected with 100 nM siRNA
specific to GREB1 or control siRNA using Oligofecta-
mineTM reagent (Invitrogen, Carlsbad, CA) in serum-
free OptiMEM-1 medium (Invitrogen) according to the
manufacture’s instructions for 4 h. One half volume of
IMEM containing 30% CCS was added after 4 h. After
24 h, the cells were treated with a dose range of E2
(10)12 to 10)9 M) or 0.01% ethanol.
MCF-7 xenograft model
MCF-7 cells (107) were inoculated subcutaneously in
the mammary fat pad region of 6-week old ovariecto-
mized athymic nude mice containing sustained-released
E2 pellets (0.72 mg/pellet, 60-day release, Innovative
Research of America, Sarasota, FL) as described pre-
viously [11]. After 4 weeks, the mice were randomized
into control (continued E2 supplementation) or E2
withdrawal (surgical removal of pellet). Tumors excised
24 and 48 h later, RNA was extracted and assayed from
GREB1 mRNA. All animal experiments were per-
formed according to a protocol approved by University
of Michigan Guideline for Use and Care of Animals in
compliance with US and UKCCR guidelines [12].
Results
We established appropriate culture conditions to de-
velop an initial data set of estrogen regulated genes in
MCF-7 cells. After 24 h of hormonal exposure, cellular
RNA was extracted and the gene expression patterns
determined using the Affymetrix U133A Genechip.
Previous studies in our laboratory have shown that
replicate analysis of the same sample yielded 99.9%
identical results indicating that the chips produce highly
reproducible patterns of expression. The intensity data
from the microarrays were normalized and modeled
using DNA-Chip Analyzer software (dChip) [7]. Results
of cluster analysis (provided as supplemental data 1)
show that the pattern of gene expression in the estrogen
depleted (vehicle control) cells was most like that of the
ICI 182,780 treated cells while the E2 induced a pattern
most similar to 10% FBS. The gene expression pattern
induced by TAM showed similarities with both groups.
Using our statistical criteria, only one gene, KIAA0575
also called GREB1 (Gene Regulated by Estrogen in
Breast Cancer 1), was repressed by both TAM and ICI
182,780 while simultaneously induced by E2.
We repeated the array experiments on two additional
ERa-positive/estrogen dependent breast cancer cell lines
BT-474 and T-47D [5]. We hypothesized that by iden-
tifying genes altered by estrogen treatment that were
common to three separate cells lines, we might reduce
the number of candidate genes involved in estrogen in-
duced growth. We used Venn analysis to generate the
diagram shown in Figure 1. In the MCF-7 cells, 674
genes were significantly altered by estrogen while 140
and 33 were altered in the T47D and BT-474, respec-
tively. Of these, only three induced genes were common
to all three cell lines and include: pS2, SDF-1 and
GREB1. Their fold induction is shown in the table. It
has been previously reported that pS2 is not involved in
cellular growth so we ruled it out as a critical regulator
[13]. In contrast, SDF-1 has been shown in one study
[14] to induce growth in breast cancer and its charac-
terization is the topic of a separate study. Since very
little is known about the role of GREB1 in estrogen
induced breast cancer growth, we chose this gene for
further characterization.
Figure 1. Venn diagram of genes significantly altered by E2 treatment
in three estrogen receptor-positive, estrogen dependent breast cancer
cell lines (MCF-7, BT-474 and T47D). Cells were grown in steroid
depleted medium for 4 days and then treated with E2 (10)8 M) for
24 h. RNA was isolated and gene expression profiles measured using
the Affymetrix U133A Genechip Arrays. Results were generated
from replicate biological samples. Only three genes were common to
each cell line and their fold induction shown in the table.
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To validate our microarray results we established
two separate a real-time PCR assays. GREB1 has three
known splice variants [15], and so one assay was de-
signed to measure the longest transcript (GRE-
B1a = 8482-bp), while the second measures the
aggregate level of all three transcripts. Measurement of
samples with both assays yielded similar results con-
firming that the level of all transcripts are regulated
coordinately (data not shown). We confirmed that in all
three cell lines GREB1 is induced by E2 and FBS but
not by the antiestrogens TAM and ICI 182,780. Treat-
ment with E2 and 10% FBS induced GREB1 mRNA
levels 23.9 ± 0.01 and 14.1 ± 0.02 fold over control,
respectively. In contrast, neither TAM nor ICI 182,780
treatments altered GREB1 levels (0.98 ± 0.05 and
0.94 ± 0.02, respectively). Similar results were observed
using the T47D and BT-474 cell lines, validating our
microarray results and confirming that GREB1 expres-
sion is regulated by estrogen in all three breast cancer
cell lines.
We examined the correlation between GREB1
expression and ERa status in a panel of breast cancer
cell lines. Shown in Figure 2 are the results for GREB
assays in 39 breast cancer cell lines and sublines of
known ERa status, plotted as the ratio of GREB1
transcripts/1000 GAPDH transcripts in decreasing or-
der from left to right. The results show that expression
of GREB1 correlated with the known estrogen receptor
status [16].
We next studied the relationship between GREB1
expression and parameters of cell growth. As shown in
Figure 3a, the proliferation over 4 days (plotted as %
change in cell number over vehicle control) induced by
E2 (304 ± 11%) was suppressed by ICI 182,780
(120 ± 2%) while ICI 182,780 alone had no effect
(102 ± 7%). Changes in proliferation were correlated
with the changes in GREB1 mRNA induction (shown
in Figure 3b). Similar data were shown in vivo. MCF-7
cells were grown as xenografts in ovariectomized
athymic nude mice implanted with sustained–release E2
pellets. After measurable tumors were established
(4 weeks), the mice were randomized into control
(continued E2 supplementation) or E2 withdrawal
(surgical removal of pellet) groups, and tumors assayed
for GREB1 expression 24 or 48 h later. GREB1
mRNA levels were lower in all four tumors after E2
pellet removal compared to control tumors (Figure 3c),
an effect that was not dependent on tumor size (ex-
pressed in mm3 under each bar) showing that GREB1
is regulated by E2 in vivo.
The dose response relationship for GREB1 induction
byE2matches that for proliferation.GREB1was induced
by E2 in all three cell lines in a dose dependant manner
(Figure 4). The greatest induction was seen in MCF-7
cells with 10)8 M E2 inducing GREB1 by 40±5 fold in
24 h. These results are consistent with the published
estrogen proliferative responses of these cells [5].
The time course of E2 induced GREB1 mRNA
expression and induction of growth were measured in
MCF-7 cells arrested by culture in estrogen-free condi-
tions for 4 days. The cells were treated with E2
(10)9 M), total RNA and cell samples for flow cytom-
etry were collected, and results are shown in Figure 5.
GREB1 is an early response gene induced 7.26 ± 0.44
fold by 2 h reaching 29.86 ± 5.35 fold by 24 h. These
changes mirrored the increase in the percentage of cells
in S-phase with increases observed at 2 h reaching
37 ± 0.99% by 24 h. This experiment was repeated
using the BT-474 and T47D cell lines with similar results
(data not shown).
To test whether inhibition of GREB1 expression
would affect growth, four synthetic small interfering
RNA (siRNA) duplexes were designed to target regions
common to all three GREB1 transcript variants. The
Figure 2. GREB1 mRNA expression levels correlate with ERa status in 39 breast cancer lines and sublines of know estrogen receptor status.
Quantitative real-time PCR was performed as described in the Methods section and data are plotted as the ratio of the log of GREB1 transcripts/
log GAPDH transcripts in decreasing order from left to right.
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efficiency of these GREB1 siRNAs was verified by
transfecting MCF-7 cells grown in 10% FBS with the
siRNAs, both individual or as a pool of duplexes.
GREB1 mRNA levels were determined 48 h later
revealing similar efficiencies. GREB1 mRNA levels were
suppressed approximately one tenth the level in cells
transfected with a control siRNA duplex with no
homology to any known sequence (Figure 6a). To fur-
ther test the efficacy and specificity of our siRNA du-
plexes, MCF-7 cells were cultured for 4 days in steroid
depleted medium, transfected with the siRNAs and then
24 h later treated with various doses of E2. After 4 days
RNA was isolated, and assayed for GREB1, PS2 and
36B4 mRNA levels by real-time PCR. Transfection with
GREB1 siRNA duplexes suppressed E2 induced
expression of GREB1 (77% decrease at 10)9 M E2)
(Figure 6b) but had no effect on PS2 or 36B4 levels
(Figure 6c and d) suggesting the GREB1 siRNA du-
plexes are specific for that gene. Data are the results of
quadruplicate samples (duplicate biologic samples from
two separate experiments) assayed in triplicate.
To determine if the suppression of GREB1 mRNA
levels by the siRNAs would have any effect on the
growth of the cells, proliferation assays were conducted
in parallel with the RNA studies described above.
MCF-7 cells were cultured for four days in steroid
Figure 3. The anti-estrogen ICI 182,780 suppresses E2 induced cell
growth and GREB1 induction in MCF-7 cells. MCF-7 cells were
culture in steroid-depleted conditions and treated with: vehicle control,
E2 (10)9), ICI 182,780 (10)7 M), or the combination. After 4 days, cell
number (a) was determined and compared GREB1 mRNA levels (b)
at 24 h. Shown are the mean and standard deviation of duplicate
samples assayed in triplicate. (c) GREB1 is regulated by E2 in vivo.
MCF-7 xenografts were withdrawn from E2 supplementation, tumors
assayed for GREB1 expression 24 or 48 h later and compared to
control (continued E2 supplementation). Tumor volumes (expressed in
mm3) are shown under each bar.
Figure 4. GREB1 induction is dose dependent. ERa-positive breast
cancer cell lines were cultured in steroid depleted conditions and then
treated with a dose range of E2 (10)12 to 10)9 M). After 24 h, RNA
was extracted and assayed for GREB1 mRNA as described in the
methods section. The mean and standard deviation of duplicate sam-
ples assayed in triplicate are shown.
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hormone free medium, then transfected with the siR-
NA duplexs. After 24 h, the cells were treated with a
dose range of E2 (10)12 to 10)9 M) and assayed for
growth on days 2–5. As expected, E2 induced the
growth of MCF-7 cells treated with control siRNA
(Figure 7a). Cells grown continuously in the steroid
depleted medium continued to grow slowly, indicative
of a low level of residual estrogen, and transfection
with the GREB1 siRNA had minimal effects. Trans-
fection with the GREB1 siRNA had a dramatic effect
on cells treated with E2. Not only was the normal
stimulation of proliferation completely abolished, but
growth was suppressed to below that seen in the cells
grown continuously in the steroid depleted medium.
There was a dose response relationship for this sup-
pression that mirrored that for proliferation seen in the
cells transfected with the control siRNA (Figure 7b).
Discussion
Previous studies to identify E2 regulated genes have fo-
cused on the gene expression patterns induced by estro-
gens and antiestrogens in single cell lines [17–22]. Our
approach was to compare the gene expression patterns
induced in three separate ERa-positive, estrogen depen-
dent breast cancer cells lines grown under identical
conditions, using multiple estrogen agonist and antago-
nist signals to narrow down the number of candidate
genes for detailed characterization. We postulated that
differentially regulated genes that are involved in estro-
gen induced growth could exhibit common patterns of
regulation in parallel to effects on proliferation in all
three cell lines, in contrast to those genes that are regu-
lated by estrogen but not directly involved in cellular
proliferation. Using this approach we identified three
Figure 5. Time course of GREB1 induction and correlation with in-
creased S-phase fraction. MCF-7 cells were cultured in steroid depleted
conditions and then treated with E2 at 10)9 M. Samples were collected
at 1, 2, 4, 8, 12 and 24 h and assayed for GREB1 mRNA levels by real-
time PCR and S-phase fraction by flow cytometry. The mean and
standard deviation of duplicate samples assayed in triplicate are
shown.
Figure 6. Efficacy and specificity of GREB1 siRNA duplexes. (a) MCF-7 cells grown in 10% FBS were transfected with individual or a pool of
duplexes and after 24 h assayed for GREB1 mRNA. MCF-7 cells were grown in steroid depleted medium, transfected with the siRNAs, after
24 h treated with E2 and assayed for GREB1 (b), pS2 (c) and 36B4 (d) mRNA on day 4. Results represent the mean and standard deviation of
quadruplicate samples (duplicate biologic samples from two separate experiments) assayed in triplicate.
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genes that were differentially expressed in MCF-7, BT-
474 and T47D breast cancer cells treated for 24 h with E2
after rigorously removing exogenous estrogens: pS2,
SDF-1 and GREB1.
Previously it has been shown that the pS2 gene,
which is regulated by estrogen in vitro [23] and in vivo
[24], is not required for estrogen induced cell prolifera-
tion and most likely plays a role protection of the gas-
trointestinal mucosal integrity [13]. This may be the
underlying reason why pS2 expression in primary breast
cancers does not provide a significantly better prediction
of hormonal therapy than estrogen receptor status alone
[25]. In contrast, studies suggest that SDF-1 may play a
role in breast cancer pathogenesis. The cytokine SDF-1
is the principle ligand for the chemokine receptor
CXCR4, a coreceptor with CD4 for the human immu-
nodeficiency virus type 1 [26]. It has been shown that
SDF-1 is a chemotactic factor and plays an important
role in breast cancer metastasis by mediating actin
polymerization and pseudopodia formation resulting in
cell migration [27]. Recently, Hall et al. have shown that
SDF-1 is induced by estrogen in MCF-7 cells and the
BG-1 ovarian carcinoma cell line and induces cellular
proliferation via autocrine/paracrine interactions with
the CXCR4 receptor [14]. Our results confirm their
conclusion that SDF-1 is an estrogen regulated gene in
MCF-7 cells and show similar regulation in two addi-
tional ERa-positive/estrogen dependant cell lines.
In the current study we have focused on GREB1
because its cellular function and its role in breast cancer
have not been established. It was originally discovered
in the human brain [28] and the mouse homolog was
Figure 7. Suppression of GREB1 by siRNA reduces cell growth. MCF-7 cells were culture in steroid-depleted conditions, transfected with a pool
of synthetic siRNA duplexes specific to GREB1 or a control siRNA, and after 24 h the cells were treated with a dose range of E2 (10)12 to
10)9 M). Changes in cell number were then assayed on days 2–5 by crystal violet staining. Growth curves for cells transfected with the control or
anti GREB1 siRNAs treated with either E2 (10)10 M) or the vehicle control (0.1% ethanol) are shown in panel A. The dose response relationship
for estrogen induced changes in cell number after 5 days of culture for cells transfected with either the control or GREB1 siRNA are shown in
panel B. Each point represents the mean and standard deviation five replicate wells.
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discovered soon after on chromosome 12 [29]. The hu-
man gene is located in the short arm of chromosome 12
(p25.1) where it spans roughly 108 kb. The longest
transcript codes for a putative 1949-aa protein with at
least four transmembrane domains and a N-myristoy-
lation domain (http://www.ncbi.nlm. nih.gov/IEB/Re-
search/Acembly). Gosh et al. were the first to show that
GREB1 is an estrogen regulated gene [15]. They showed
that it is an early response gene directly regulated by ER
and suggested that it plays an important role in hor-
mone-responsive tissues and cancer [15]. These results
have been confirmed recently by Lin et al. who found
GREB1 to be one of the few ER responsive genes shared
by MCF-7 and T-47D cells and show using chromatin
immunoprecipitation that ligand bound ER binds to the
predicted estrogen response element in the putative
GREB1 promoter region [30].
Having identified GREB1 as a gene consistently
regulated in parallel with proliferation by estrogenic and
anti-estrogenic treatments in three independent cell
lines, and that its expression is significantly associated
with ERa positivity in breast cancer cell lines, we set out
to determine if GREB1 might be involved directly in
estrogen stimulated growth. We used the powerful
technique of siRNA mediated gene ‘knockdown’ and
found that when GREB1 expression was suppressed,
not only were the cells no longer stimulated to prolif-
erate by E2, but in fact their growth was inhibited by E2
in a dose dependent fashion. This effect does not seem to
be the result of a global alteration of the response of the
cells to E2 since the induction of pS2 was not affected by
GREB1 suppression. This result also suggests that the
growth effects are not simply the result of global effects
on mRNA levels or transcription, an idea further sup-
ported by the fact that 36B4 levels remain unaltered.
While it remains possible that the GREB1 siRNA’s may
be affecting the levels of other genes that we have not
examined, the fact that four independent GREB1 tar-
geted siRNA’s have very similar effects makes this quite
unlikely. The use of the irrelevant siRNA duplex pro-
vides a control for the global, target-independent effects
of transfection with siRNAs which have been reported
[31].
It is possible that suppressing GREB may simply
suppress proliferation, irrespective of whether that
growth is stimulated by E2. Since GREB1 is itself an
estrogen responsive protein, this is somewhat of a
semantic issue and is quite difficult to test since none of
the estrogen receptor negative breast cancer cells express
GREB1 at significant levels, making them poor systems
in which to test the effects of GREB1 suppression
independent of the effects of estrogen. The function of
GREB1 remains a mystery and few hints to its function
are provided by analysis of the structure of the protein.
Much work remains to be done to establish the role
of GREB1 in estrogen stimulated proliferation but the
data presented here suggest the exciting possibility that
GREB1 may be a valuable new target for the treatment
of breast cancer.
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